US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

In a powerful act of compassion and community, Starr’s Mill High School organized an early graduation for rising senior ...

As a result of being afflicted with PLS, he is unable to walk and is dependent on a caregiver for help with his daily needs.

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

Purpose Amyotrophic lateral sclerosis (ALS) presents with varying degrees of brain degeneration that can extend beyond the corticospinal tract (CST). Furthermore, the clinical course and progression ...

Neurizon Therapeutics has announced it has received positive feedback from the US Food and Drug Administration (FDA) on its ...

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Documenting his experiences has proven to be the outlet Darin Nakakihara needs in the wake of his ALS diagnosis.

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in pediatric-onset MS and late-onset MS require specific considerations ...